Literature DB >> 26430426

Diagnostic value of urinary protein and creatinine in combination with renal ultrasound examination in early renal damage of patients with hypertension.

Jihong Zhu1, Ke Wen2, Hongwen He3.   

Abstract

OBJECTIVE: To evaluate the diagnostic value of urinary protein and creatinine in combination with renal Doppler ultrasound examination in early renal damage of patients with hypertension.
METHODS: One hundred twenty two hypertensive patients who were treated in our hospital from December 2013 to June 2014 were selected for this study, including 33, 41 and 48 cases of Stage I, Stage II and Stage III hypertension respectively. Meanwhile, 30 healthy subjects were selected as the control group. They received urinary protein, creatinine and renal Doppler ultrasound examination.
RESULTS: The urinary protein levels of Stage I, II and Stage III hypertensive patients were significantly different from that of the control group (p<0.05). Urinary creatinine levels were similar (p>0.05) in stage I and II but different from control (p<0.05) in stage III. Doppler ultrasound examination showed that Stage I hypertensive patients had similar renal longest diameter (RLD), renal parenchymal thickness (RPT) and ratio of RPT/renal sinus thickness to those of the control group (p>0.05), and RLDs of Stage II hypertensive patients and the control group were not significantly different (p>0.05).
CONCLUSION: Urinary protein and creatinine levels in combination with renal Doppler ultrasound examination could diagnose early renal damage in patients with hypertension.

Entities:  

Keywords:  Creatinine; Hypertension; Ultrasound examination; Urinary protein

Year:  2015        PMID: 26430426      PMCID: PMC4590400          DOI: 10.12669/pjms.314.7513

Source DB:  PubMed          Journal:  Pak J Med Sci        ISSN: 1681-715X            Impact factor:   1.088


INTRODUCTION

As a common cardiovascular disease,1,2 hypertension is mainly manifested as hemodynamic changes and injuries to many organs as it further progresses.3 Being one of the damaged target organs, the kidney is endangered by hypertension that increases the risk of complicated proteinuria. End-stage renal disease has been ascribed to hypertension-induced renal damage as one of the reasons,4-6 so it is important to diagnose early renal damage in hypertensive patients to improve the therapeutic effects and prognosis. Since the renal status and arterial hemodynamics of hypertensive patients change before renal function does, we herein assessed the diagnostic value of urinary protein-creatinine monitoring in combination with renal ultrasound examination in early renal damage of patients with hypertension in different stages.

METHODS

Baseline clinical data

This study was approved by the ethics committee of our hospital and written consent had been obtained from all patients. A total of 122 hypertensive patients who were treated in our hospital from December 2013 to June 2014 were selected for this study, including 33, 41 and 48 cases of Stage I, Stage II and Stage III hypertension respectively. The patients comprised 58 males and 64 females, aged 34-63 years old (average: 46.2±4.1). Meanwhile, 30 healthy subjects were selected as the control group, including 18 males and 12 females, aged 32-62 years old (average: 45.1±3.9). The baseline clinical data of all patients and the control group were similar.

Methods

The levels of urinary protein and creatinine were detected. PHILIPS color Doppler ultrasound scanner with the probe frequency of 2-5 MHz was used to observe the renal status and to measure renal longest diameter (PLD), renal parenchymal thickness (RPT) and renal sinus thickness (RST). Ratio of RPT/RST was also calculated. In the meantime, blood fillings of the aorta, segmental arteries and arch arteries were observed. Blood flow parameters of the main renal artery, intrasinus segmental arteries and bilateral renal interlobar arteries were determined at about 1 cm of the renal hilum by pulse Doppler ultrasound. The angle between sound beam and direction of blood flow was <60°. Sampling was performed in triplicate at the central arterial lumen (1-3 mm), and peak systolic velocity (PSV), end-diastolic velocity (EDV) and resistive index (RI) [RI = (PSV-EDV)/PSV] of renal arteries were recorded. Renal blood-flow rate Q was calculated. Q (ml/min) = π×D2/4×Vmean×60 [D is the inner diameter of the main renal artery, Vmean=(PSV+EDV)/2].

Statistical analysis

All data were input by EXCEL and processed by SPSS 18.0. The numerical data were compared by Chi-square test. The categorical data were expressed as (x±s). The data conforming to normal distribution were subjected to t test. P<0.05 was considered statistically significant.

RESULTS

General information

Age, gender ratio and basic diseases of hypertensive patients and the control group were similar (P>0.05).

Urinary protein and creatinine levels

The urinary protein levels of Stage I, II and Stage III hypertensive patients were significantly different from that of the control group (p<0.05), but their urinary creatinine levels were similar (p>0.05) to control in stage I and II were significantly different from that of the control group (p<0.05) in stage III patients (Table-I).
Table-I

Urinary protein and creatinine levels.

GroupCase No.Urinary protein (mg/L)Urinary creatinine (mmol/d)
Control300.59±0.4912.11±2.42
Stage I hypertension331.20±1.1514.37±4.11*
Stage II hypertension412.73±1.4116.44±3.32*
Stage III hypertension484.75±2.8023.31±3.31

Compared with control group, p>0.05;

Compared with control group, p<0.05.

Urinary protein and creatinine levels. Compared with control group, p>0.05; Compared with control group, p<0.05.

RLD, RPT and RPT/RST

Stage I hypertensive patients had similar RLD, RPT and RPT/RST to those of the control group (p>0.05). RLDs of Stage II hypertensive patients and the control group were not significantly different (p>0.05), but with significantly different RPT and RPT/RST (p<0.05) seen in comparison with the control group. Stage III hypertensive patients had significantly different RLD, RPT and RPT/RST (p<0.05) (Table-II).
Table-II

Renal ultrasound results.

GroupCase No.RLD (cm)RPT (cm)RPT/RST
Control3010.26±1.562.14±0.430.84±0.24
Stage I hypertension3310.25±1.46*1.97±0.36*0.78±0.25*
Stage II hypertension419.97±1.16*1.47±0.320.60±0.19
Stage III hypertension489.07±0.941.20±0.210.47±0.20

Compared with control group, p>0.05;

Compared with control group, p<0.05.

Renal ultrasound results. Compared with control group, p>0.05; Compared with control group, p<0.05.

Detection rates of arteries by renal ultrasound

All the main renal arteries and segmental arteries were detected. As to arch arteries, the detection rate of the control group was 100%, and those of Stage I, Stage II and Stage III hypertension groups were 93.94%, 19.51% and 0% respectively (Table-III).
Table-III

Detection rates of renal arch arteries.

GroupCase No.DetectedUndetected
Control3030 (100)0
Stage I hypertension3331 (93.94)2 (6.06)
Stage II hypertension418 (19.51)33 (80.49)
Stage III hypertension48048 (100)
Detection rates of renal arch arteries.

Blood flow parameters of the main renal artery and segmental arteries

PSV, EDV and RI of the main renal artery and segmental arteries in Stage I hypertension group were similar to those of the control group (p>0.05). Stage II hypertensive patients had similar PSV to that of the control group (p>0.05) but significantly different EDV and RI from those of control (p<0.05). PSV, EDV and RI of Stage III hypertension group were significantly different from those of the control group (p<0.05) (Table-IV and Table-V).
Table-IV

Blood flow parameters of the main renal artery.

GroupCase No.Main renal artery
PSV (cm/s)EDV (cm/s)RI
Control3061.12±10.4933.41±6.110.64±0.07
Stage I hypertension3363.08±11.32*34.21±7.42*0.65±0.09*
Stage II hypertension4158.23±8.41*15.56±4.820.74±0.08
Stage III hypertension4844.41±9.3111.14±3.160.78±0.05

Compared with control group, p>0.05;

Compared with control group, p<0.05.

Table-V

Blood flow parameters of segmental arteries.

GroupCase No.Segmental artery
PSV (cm/s)EDV (cm/s)RI
Control3044.51±9.8117.09±5.420.63±0.09
Stage I hypertension3345.18±7.42*17.68±5.72*0.65±0.06*
Stage II hypertension4140.32±8.43*10.26±4.610.73±0.08
Stage III hypertension4833.41±7.158.64±1.860.77±0.10

Compared with control group, p>0.05;

Compared with control group, p<0.05.

Blood flow parameters of the main renal artery. Compared with control group, p>0.05; Compared with control group, p<0.05. Blood flow parameters of segmental arteries. Compared with control group, p>0.05; Compared with control group, p<0.05.

Renal blood-flow rates

The renal blood-flow rates of Stage I and Stage II hypertensive patients (761.48±226.58 and 669.41±149.42 ml/minute respectively) were similar to that of the control group (709.45±125.42 ml/min) (p>0.05), but the rates of Stage III hypertension (404.82±169.52 ml/min) and control groups differed significantly (p<0.01) (Fig.1).
Fig.1

Renal blood-flow rates of control and Stage III hypertension groups.

Renal blood-flow rates of control and Stage III hypertension groups.

DISCUSSION

Hypertension is mainly clinically manifested as increase in blood pressure which, if continues, affects the structures and functions of vital organs (e.g. heart, brain and kidney) and eventually leads to their failures.2-4 The kidneys predominantly regulate the water-electrolyte balance and have several endocrine functions. Nowadays, more hypertensive patients are prone to renal damage-induced chronic renal insufficiency, 20% of whom finally suffer from end-stage renal disease.6-9 Therefore, diagnosing early renal damage of these patients plays a crucial role in improving the treatment outcomes and prognosis. In this study, 122 patients with different degrees of hypertension were subjected to urinary proteinand creatinine examinations in combination with renal ultrasound examination. As hypertension was aggravated, the levels of urinary protein and creatinine increased. However, upon renal damage, the changes of renal status and arterial hemodynamic parameters preceded those of urinary protein and creatinine.9,10 We herein performed renal ultrasound examination to measure RLD, RPT and RST in different stages of hypertension. Stage I hypertensive patients had similar RLD, RPT and RPT/RST to those of the control group (p>0.05), and RLDs of Stage II hypertensive patients and the control group were not significantly different (p>0.05), but with significant differences between RPT and RPT/RST (p<0.05) compared with the control group. Stage III hypertensive patients had significantly different RLD, RPT and RPT/RST (p<0.05). The results suggested that the renal morphology of Stage I hypertensive patients remained almost unchanged due to mild damage to the renal parenchyma. In contrast, renal arterioles of Stage II and Stage III hypertensive patients underwent continuous sclerosis, accompanied by nephron atrophy and disappearance, obvious attenuation of the renal parenchyma, and plummet in RPT/RST. All of the main renal arteries and segmental arteries were detected. As to arch arteries, the detection rate of the control group was 100%, and those of Stage I, Stage II and Stage III hypertension groups were 93.94%, 19.51% and 0% respectively, which were consistent with the outcomes of previous literatures.11,12 PSV, EDV and RI of the main renal artery and segmental arteries in Stage I hypertension group were similar to those of the control group (p>0.05). Stage II hypertensive patients had similar PSV to that of the control group (p>0.05) and significantly different EDV and RI from those of control (p<0.05). PSV, EDV and RI of Stage III hypertension group were significantly different from those of the control group (p<0.05). It has previously been reported that the incidence rate of renal arteriolosclerosis is positively correlated with the degree and duration of hypertension.12-15 In this study, Stage I and Stage II hypertensive patients were free from renal vascular changes and subject to moderate changes respectively, whereas Stage III ones suffered from severe renal arteriolosclerosis. Furthermore, the renal blood-flow rate of Stage II hypertension group was slightly lower than that of Stage I group (p>0.05), but the rate of Stage III group decreased significantly (p<0.05) owing to severe nephron damage.

CONCLUSION

In summary, urinary protein and creatinine monitoring in combination with renal Doppler ultrasound examination was able to accurately, and economically diagnose early renal damage of patients with hypertension, which was of great significance for effective treatment and prognosis.
  15 in total

1.  Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension.

Authors:  Felix Mahfoud; Bodo Cremers; Julia Janker; Britta Link; Oliver Vonend; Christian Ukena; Dominik Linz; Roland Schmieder; Lars Christian Rump; Ingrid Kindermann; Paul Andrew Sobotka; Henry Krum; Bruno Scheller; Markus Schlaich; Ulrich Laufs; Michael Böhm
Journal:  Hypertension       Date:  2012-06-25       Impact factor: 10.190

Review 2.  Hypertension and kidney disease.

Authors:  E Ritz
Journal:  Clin Nephrol       Date:  2010-11       Impact factor: 0.975

3.  Central pulse pressure and aortic stiffness determine renal hemodynamics: pathophysiological implication for microalbuminuria in hypertension.

Authors:  Junichiro Hashimoto; Sadayoshi Ito
Journal:  Hypertension       Date:  2011-10-03       Impact factor: 10.190

4.  Usefulness of the resistive index in renal Doppler ultrasonography as an indicator of vascular damage in patients with risks of atherosclerosis.

Authors:  Tatsuo Kawai; Kei Kamide; Miyuki Onishi; Hiroko Yamamoto-Hanasaki; Yoshichika Baba; Kazuhiro Hongyo; Izumi Shimaoka; Yuji Tatara; Yasushi Takeya; Mitsuru Ohishi; Hiromi Rakugi
Journal:  Nephrol Dial Transplant       Date:  2011-03-03       Impact factor: 5.992

Review 5.  Hypertensive renal damage.

Authors:  M R Weir; M K Hise
Journal:  Cardiovasc Clin       Date:  1991

6.  Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea.

Authors:  Adam Witkowski; Aleksander Prejbisz; Elżbieta Florczak; Jacek Kądziela; Paweł Śliwiński; Przemysław Bieleń; Ilona Michałowska; Marek Kabat; Ewa Warchoł; Magdalena Januszewicz; Krzysztof Narkiewicz; Virend K Somers; Paul A Sobotka; Andrzej Januszewicz
Journal:  Hypertension       Date:  2011-08-15       Impact factor: 10.190

7.  Increased renal resistive index in patients with essential hypertension: a marker of target organ damage.

Authors:  R Pontremoli; F Viazzi; C Martinoli; M Ravera; C Nicolella; V Berruti; G Leoncini; N Ruello; P Zagami; G P Bezante; L E Derchi; G Deferrari
Journal:  Nephrol Dial Transplant       Date:  1999-02       Impact factor: 5.992

8.  Urinary biomarkers track the progression of nephropathy in hypertensive and obese rats.

Authors:  Qin Zhang; Kelly J Davis; Dana Hoffmann; Vishal S Vaidya; Ronald P Brown; Peter L Goering
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

9.  Early predictors of 15-year end-stage renal disease in hypertensive patients.

Authors:  H M Perry; J P Miller; J R Fornoff; J D Baty; M P Sambhi; G Rutan; D W Moskowitz; S E Carmody
Journal:  Hypertension       Date:  1995-04       Impact factor: 10.190

Review 10.  Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis.

Authors:  R K Morris; R D Riley; M Doug; J J Deeks; M D Kilby
Journal:  BMJ       Date:  2012-07-09
View more
  1 in total

1.  Diagnostic efficacy and influence factors of urinary protein/creatinine ratio replacing 24-h urine protein as an evaluator of proteinuria in children.

Authors:  Panpan Zhai; Yanjie Huang; Shangsai Yue; Xiaoqing Yang; Jinghui Luo; Yanan Zhang; Xiaofeng Mei; Liangliang Bi; Wensheng Zhai; Xianqing Ren; Yingbao Yang; Xiaoke Zheng; Tatsuo Yamamoto
Journal:  Int Urol Nephrol       Date:  2021-10-19       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.